DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  • STATUS
    Not Recruiting
  • End date
    Sep 7, 2024
  • participants needed
    600
  • sponsor
    Daiichi Sankyo, Inc.
Updated on 26 January 2021
Investigator
Principal Investigator
Primary Contact
Macquarie University Hospital (1.3 mi away) Contact
+69 other location
lapatinib
capecitabine
HER2
trastuzumab
adjuvant therapy
erbb2
her2/neu-positive breast cancer
immunostimulant
mammogram

Summary

This study will compare DS 8201a to standard treatment.

Participants must have HER2 breast cancer that has been treated before.

Their cancer:

  • cannot be removed by an operation
  • has spread to other parts of the body

Description

The study is designed to compare DS 8201a versus standard of care (investigator's choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.

Details
Condition Breast Cancer
Treatment Capecitabine, Trastuzumab, Lapatinib, Trastuzumab deruxtecan
Clinical Study IdentifierNCT03523585
SponsorDaiichi Sankyo, Inc.
Last Modified on26 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note